• Users Online: 245
  • Print this page
  • Email this page
Year : 2020  |  Volume : 4  |  Issue : 2  |  Page : 54-59

Clinical prognostic factors and treatment outcomes in patients with small cell carcinoma of the cervix: A single institution-based retrospective study

Department of Radiation Oncology, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India

Correspondence Address:
Niketa Thakur
Department of Radiation Oncology, Gujarat Cancer and Research Institute, New Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/oji.oji_18_20

Rights and Permissions

Introduction: Small cell carcinoma of the cervix (SCCC) is relatively uncommon among cervical malignancies and is more likely to develop lymph node and distant metastasis compared to the common squamous histological variant. There is a lack of knowledge about potential prognostic factors, optimal treatment modalities, and survival outcome of SCCC. Aim: The aim of this study is to correlate clinicopathologic parameters and different treatment schedules with survival outcomes of SCCC as progression-free survival (PFS) and overall survival (OS). Materials and Methods: A retrospective study was conducted on diagnosed SCCC patients taking treatment from January 2005 to December 2014. Results: A total of 21 patients were analyzed. The median age of presentation was 47 years. All the patients presented at an advanced stage (IIB-IVB) with high-grade histological differentiation. The median PFS and OS were 5 and 6 months, respectively. The patient receiving multi-agent platinum- and etoposide-based radical concurrent chemoradiotherapy (CCRT) plus brachytherapy had significantly better PFS (P = 0.028) and a trend toward better OS versus other treatment modalities. The median OS was found to be significantly poor in SCCC patients having an additional neuroendocrine component, not receiving brachytherapy after CCRT, and not receiving prophylactic cranial irradiation after radical radiotherapy (P < 0.05). Cisplatinum- plus etoposide-based CCRT schedule had a trend toward better PFS and OS than that of only cisplatinum-based CCRT (P > 0.05). Furthermore, a trend toward better OS was seen for age >40 years, tumor size ≤4 cm, and lymph node-negative status. Relapse was seen in 42.9% of the cases over a 7-month median follow-up. Conclusions: CCRT using multi-agent platinum- plus etoposide-based chemotherapy followed by brachytherapy remains the mainstay of treatment in locally advanced SCCC. The prognostic factors should be considered for customizing treatment.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded112    
    Comments [Add]    

Recommend this journal